肿瘤细胞治疗研究
英文原题：Waldenström macroglobulinemia: a challenging case treated with anti-CD19 CAR-T cell therapy.
华氏巨球蛋白血症（WM）的特征是淋巴浆细胞性淋巴瘤并伴有大量单克隆免疫球蛋白M（IgM）蛋白（Owen等，2003）。
Waldenstr m巨球蛋白血症（WM）以淋巴浆细胞淋巴瘤伴大量单克隆免疫球蛋白M（IgM）蛋白为特征（Owen等，2003）。常见体征和症状包括贫血导致的疲劳、淋巴结肿大、肝脾肿大、血小板减少、高黏滞相关症状以及周围神经病变等。尽管WM治疗取得了显著进展，但这种惰性淋巴瘤仍无法治愈，患者结局差异很大（Ruan等，2020）。近年来，靶向分化簇19（CD19）的CAR-T（CAR-T）细胞疗法在B细胞恶性肿瘤治疗中显示出前所未有的缓解率和持久性。在本报告中，我们描述了一例具有挑战性的WM病例，累及多个髓外部位，复发，并且对化疗、免疫治疗和靶向治疗难治。在接受抗CD19 CAR-T细胞治疗后，肿瘤负荷显著降低，截至本报告撰写时患者病情保持稳定。WM IgM WM WM BTK / CD19 T CAR-T CAR-T WM CAR-T / WM . WM IgM WM WM BTK / CD19 T CAR-T CAR-T WM CAR-T / WM
Waldenstr m macroglobulinemia (WM) is characterized by lymphoplasmacytic lymphoma associated with large amounts of monoclonal immunoglobulin M (IgM) protein (Owen et al., 2003). Common signs and symptoms include fatigue due to anemia, lymph node enlargement, hepatosplenomegaly, thrombocytopenia, symptoms related to high viscosity, and peripheral neuropathy, among others. Despite significant advances in WM treatment, this type of indolent lymphoma remains incurable, with a wide array of patient outcomes (Ruan et al., 2020). In recent years, chimeric antigen receptor T (CAR-T) cell therapy targeting cluster of differentiation 19 (CD19) has shown unprecedented response rates and durability in the treatment of B-cell malignancies. In this report, we describe a challenging case of WM that involved multiple extramedullary sites, relapsed, and was refractory to chemotherapy, immunotherapy, and targeted therapy. After anti-CD19 CAR-T cell therapy, the tumor burden significantly decreased and the patient's condition remained stable at the writing of this report. WM IgM WM WM BTK / CD19 T CAR-T CAR-T WM CAR-T / WM . WM IgM WM WM BTK / CD19 T CAR-T CAR-T WM CAR-T / WM
MEMBER ACCOUNT
登录成功会直接打开下一页。
